AUTO1

Phase 2Cell therapy

AAutolus Limited

AUTO1 is one of 14 biologic programs targeting Acute Lymphoblastic Leukaemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Lymphoblastic LeukaemiaActive, not recruiting

Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaRecruiting

Acute Lymphoblastic LeukaemiaPhase 2

Active, not recruiting

Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaPhase 1

Recruiting

Competition

Competitive Landscape

14 competitors in Acute Lymphoblastic Leukaemia

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 2

3 2

Mesnex

BBaxter Healthcare Corporation

Phase 2

2 3

Campath

GGenzyme, a Sanofi Company

Phase 2

1 4

Fludara

Sanofi

Phase 1

3 5

Tepadina

Jazz Pharmaceuticals

Preclinical

1 6

AUTO1

AAutolus Limited

Phase 2

1 7

Noxafil

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 8

Grafapex

MMedexus Pharma, Inc.

Preclinical

1 9

Busulfex

Akero Therapeutics

Preclinical

1 10

CAR-T Cell Therapy

TThe First Affiliated Hospital of Soochow University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

NCT06173518

Q2 2029

Phase 1/2Active, not recruiting

Acute Lymphoblastic Leukaemia

NCT04404660

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukaemia1 trial

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Active, not recruiting·AAutolus Limited·Phase 1/2·NCT04404660·153 enrolled

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia1 trial

A Single-Arm, Open-Label, Multicenter, Phase 1b/2 Study Evaluating the Safety and Efficacy of AUTO1 (Obecabtagene Autoleucel [Obe-cel]) in Pediatric Patients With CD19-positive Relapsed/Refractory (R/R) B Cell Acute Lymphoblastic Leukemia (B ALL) or R/R Aggressive Mature B Cell Non-Hodgkin Lymphoma (B NHL).

Recruiting·AAutolus Limited·Phase 1·NCT06173518·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AUTO1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AUTO1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AUTO1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Autolus Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: AAutolus Limited

AUTO1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2029

Trials by Indication[1]

Acute Lymphoblastic Leukaemia1 trial

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia1 trial

References

Drug Info

Quick Facts

Related News